A Zarkar
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003
STAMPEDE Investigators, Parikh O, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Protheroe A, Rudman S, Srihari N, James N, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Brown J, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. Ann Oncol 2020; 31:442.
31.01.2020Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003
31.01.2020Ann Oncol 2020; 31:442
STAMPEDE Investigators, Parikh O, O'Sullivan J M, Omlin Aurelius, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Protheroe A, Rudman S, Srihari N N, James N D, Parmar M K B, Sydes M R, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J S, Simms M, Brown J, Russell J M, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C D, Attard G, Amos C L, Hoyle A, Ingleby F C, Ali A, Dearnaley D P, Douis H, Gilbert D, Ritchie A W S, Parker C C, Millman R, Matheson D, Mason M D, Malik Z, MacNair A, Langley R E, Jones R J, Gillessen S, Clarke N W
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
James N, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Brown J, Parikh O, Protheroe A, Rudman S, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Srihari N, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 2019
27.09.2019Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
27.09.2019Ann Oncol 2019
James N D, O'Sullivan J M, Omlin Aurelius, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Brown J, Parikh O, Protheroe A, Rudman S, Parmar M K B, Sydes M R, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J S, Simms M, Srihari N N, Russell J M, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C D, Attard G, Amos C L, Hoyle A, Ingleby F C, Ali A, Dearnaley D P, Douis H, Gilbert D, Ritchie A W S, Parker C C, Millman R, Matheson D, Mason M D, Malik Z, MacNair A, Langley R E, Jones R J, Gillessen S, Clarke N W